Effect of Quercetin Supplementation on Endometriosis Outcomes

National Nutrition and Food Technology Institute

Status: Enrolling

Conditions: Endometriosis

Treatments: Dietary Supplement: Quercetin; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05983224

43003154

Details and patient eligibility

About

Quercetin is a polyphenol compound that possesses anti-inflammatory properties and can be found in various food sources like apples, berries, cabbage, and onions. In Park et al.'s study, it was discovered that quercetin led to a significant decrease in the proliferation of endometriosis cells. Furthermore, quercetin also triggered apoptosis in endometriosis cells in vitro and reduced the size of endometriosis lesions in vivo. Nevertheless, as of now, there have been no studies conducted in Iran or worldwide that explore the effects of quercetin supplementation on individuals with endometriosis. Hence, the aim of this study is to investigate the impact of quercetin supplementation on factors such as glycemic status, lipid profile, oxidative stress, inflammation, growth factors, adiponectin, sex hormones, and anthropometric indicators in women suffering from endometriosis.

Full description

The participants in the study were randomly assigned to two groups: the intervention group and the control group. The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks. On the other hand, the control group will be given a placebo. Blood samples will be collected before and after the intervention to measure changes in blood lipid profile, fasting blood sugar, sex hormones (testosterone, estrogen, progesterone), TNFα, IL-6, adiponectin, IGF1, HbA1C, SHBG, FSH, LH, and plasma total antioxidant capacity.

Enrollment: 50 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Willing to cooperate and complete the informed consent form.
• Diagnosed endometriosis using laparoscopy and histopathological tests.
• In the age group of 18 to 40 years.
• Having a regular menstrual cycle.
• Having a body mass index between 18.5 and 30.

Exclusion criteria

• Using hormonal medications or intrauterine treatments for a minimum of three months prior to collecting a sample.
• Having immune system disorders, persistent infections, diabetes, or any conditions like polyps and fibroids within the uterine cavity.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups, including a placebo group

Quercetin

Experimental group

Description:

The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.

Treatment:

Dietary Supplement: Quercetin

Placebo

Placebo Comparator group

Description:

The Placebogroup will receive Placebo tablets daily, after breakfast and lunch, for twelve weeks.

Treatment:

Other: Placebo